Eventide Asset Management, LLC Nektar Therapeutics Transaction History
Eventide Asset Management, LLC
- $4.71 Billion
- Q1 2025
A detailed history of Eventide Asset Management, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Eventide Asset Management, LLC holds 6,650,000 shares of NKTR stock, worth $163 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
6,650,000
Previous 6,650,000
-0.0%
Holding current value
$163 Million
Previous $6.18 Million
26.88%
% of portfolio
0.1%
Previous 0.12%
Shares
3 transactions
Others Institutions Holding NKTR
# of Institutions
158Shares Held
122MCall Options Held
1.18MPut Options Held
64.6K-
Black Rock Inc. New York, NY15.2MShares$371 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$301 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.79MShares$191 Million0.24% of portfolio
-
Acadian Asset Management LLC Boston, MA7.3MShares$179 Million0.01% of portfolio
-
Primecap Management CO Pasadena, CA5.35MShares$131 Million0.0% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $4.59B
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...